Drugs / AV-203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01603979 | May 2012 → Dec 2014 | cancer | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-08-14 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China aveooncology.com ↗
Under the terms of a March 2016 agreement, the acceptance of this IND triggers a $2 million milestone payment to AVEO from CANbridge Life Sciences. |
| 2017-12-21 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Regulatory CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China canbridgepharma.com ↗ |
| 2014-05-31 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting aveooncology.com ↗
Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. |
All press releases naming this drug 11 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01603979 ↗ |
| Known as | CAN-017 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109401 ↗ |
| Action | Inhibit | “inhibits ERBB3 activities” NCT01603979 ↗ |
| Modality | Monoclonal antibody | “humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody” NCT01603979 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT01603979 ↗ |
| Target | ERBB3 | “targets the receptor tyrosine kinase (RTK) ERBB3” NCT01603979 ↗ |